Stay up-to-date with current information and resources

Register with cardeneiv.com and you'll receive valuable information and resources, as they become available, to keep you current and help ensure you can meet the treatment needs of your patients.

For US Healthcare Professionals Only

Ready-to-use CARDENE® I.V. (nicardipine hydrochloride) for blood pressure reduction in neuroemergencies

Key considerations for choosing an antihypertensive agent in neuroemergencies

Key considerations for choosing an antihypertensive agent in neuroemergencies
Desired Characteristics Ready-to-use CARDENE® I.V. (nicardipine hydrochloride)
Rapid onset of action1
  • BP begins to fall within minutes2
Rapid offset of action1
  • 50% offset of action in about 30 minutes2
  • Plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes)2
Minimal preparation required1
  • Premixed and ready to use2
Predictable dose repsonse requiring few dose adjustments1
  • Formulation allows for rapid or gradual titration2
  • Effect on BP significantly correlated with plasma concentrations2
No invasive BP monitoring required1
  • Close monitoring of BP and heart rate by means appropriate to the clinical setting is necessary2
  • The most common adverse reactions (>3%) are headache, nausea/vomiting, hypotension, and tachycardia2

CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.

CARDENE I.V. is not indicated for the treatment or prevention of AIS, ICH, or SAH

CARDENE I.V. achieved rapid BP reduction in patients with AIS, ICH, or SAH, with control maintained over 24 hours3

30 Minutes* to Achieve Goal BP

In a prospective, pseudo-randomized study, patients with AIS, ICH or SAH achieved rapid SBP reduction, with control maintained over 24 hours.In a prospective, pseudo-randomized study, patients with AIS, ICH or SAH achieved rapid SBP reduction, with control maintained over 24 hours.


Adapted from Liu-DeRyke, 2013.
*Median.

A prospective, pseudo-randomized study of patients who presented to the ED with primary ICH (n=16), SAH (n=1), or AIS (n=9) receiving CARDENE I.V. for 24 hours. CARDENE I.V. was administered at 5 mg/hr and increased every 15 minutes by 2.5 mg/hr until target SBP range was reached or a maximum of 15 mg/hr was achieved. BP goals were defined using current consensus recommendations. Vital signs (BP and HR) were taken every 15 minutes until goal BP was achieved.3

Did you know?

In AIS, management of hypertension is key in the timing of thrombolytic therapy?4

FOR US HEALTHCARE PROFESSIONALS

The information provided in this website is intended for US healthcare professionals only.

I certify that I am a US healthcare professional.

Yes   No